Clinical trial
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the…
NCT00305188 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00305188 |
|---|---|
| Title | Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. |
| Official title | A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastases, Colorectal Neoplasms, Colorectal Carcinoma |
| Intervention type | Drug |
| Interventions | Xaliproden (SR57746A), Placebo, Oxaliplatin, 5-Fluorouracil, Leucovorin |
| Enrollment | 879 |
| Start date | Dec 1, 2005 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Mar 21, 2006 |
| Last update posted | May 4, 2016 |
| Countries | Argentina, Australia, Brazil, Canada, Chile, Germany, Hungary, Italy, Poland, Portugal, Spain, United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: